FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/BPC-157 Study Shows Promise in Accelerating Recovery from Hamstring Injuries
研究ライブラリに戻る

BPC-157 Study Shows Promise in Accelerating Recovery from Hamstring Injuries

May 25, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

BPC-157 Study Shows Promise in Accelerating Recovery from Hamstring Injuries

A new clinical trial investigating pentadecapeptide BPC 157 for treating acute hamstring muscle strains has begun recruiting participants. Sponsored by Hudson Biotech, this Phase 2 study aims to evaluate whether BPC-157 can expedite structural healing and improve functional recovery compared to a placebo.

Background

Hamstring muscle injuries are common among athletes and individuals engaged in high-intensity physical activities. These injuries can cause significant downtime and disrupt training schedules. Currently, rehabilitation programs focus on gradual reconditioning of the injured muscles, but there is increasing interest in exploring peptide therapy as an adjunctive treatment to accelerate recovery.

BPC-157 is a synthetic pentadecapeptide that has shown promise in various preclinical studies for its anti-inflammatory and tissue-healing properties. Its potential benefits include reducing muscle inflammation and promoting faster regeneration of damaged tissues, which could be particularly useful in sports medicine where quick return-to-play timelines are crucial.

Key Details

The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study involving participants with acute grade II hamstring muscle strains. The primary objective is to assess whether BPC-157 can reduce the time required for full recovery and enhance structural healing as measured by MRI scans at Day 14 post-injury.

Participants will receive either BPC-157 or a placebo in addition to following a standardized rehabilitation program that includes physical therapy sessions. The study period is relatively short, lasting only two weeks, but this timeframe allows researchers to capture early recovery markers and changes in injury volume.

The primary endpoints of the trial are the time needed for athletes to return to unrestricted sports activities and the reduction in MRI-assessed injury volume at Day 14 compared to baseline measurements. Secondary outcomes will include pain levels, muscle strength assessments, and patient-reported functional status during follow-up visits.

Key Takeaways

  • Accelerated Recovery: The study aims to determine if BPC-157 can help athletes recover faster from hamstring injuries.
  • Structural Healing: Researchers will measure the effectiveness of BPC-157 in reducing injury volume using MRI scans.
  • Double-blind, Placebo-Controlled Design: This rigorous trial design helps ensure unbiased results and adds credibility to the findings.
  • Standardized Rehabilitation Program: Participants receive consistent care alongside peptide therapy, allowing for fair comparison with placebo.

What This Means

This clinical trial represents a significant step forward in exploring BPC-157’s potential as an effective treatment option for hamstring muscle injuries. If successful, it could provide athletes and clinicians with a new tool to speed up recovery times and minimize downtime associated with these common sports-related injuries.

The results of this study will be closely watched by the peptide research community, as positive outcomes could pave the way for further investigations into BPC-157’s therapeutic applications. Additionally, understanding its mechanisms may lead to broader implications in regenerative medicine and tissue repair beyond sports injuries.

---

Source: ClinicalTrials.gov — Published 2026-02-27

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。